Laekna, Inc. Advances Obesity Drug with New Trial Phase

Laekna, Inc. (HK:2105) has released an update.

Laekna, Inc. has announced the initiation of subcutaneous dosing in their Phase I clinical trial of LAE102, a promising monoclonal antibody for obesity treatment. The trial is progressing well, with early signs of target engagements and expected biomarker changes already observed. The company aims to complete this study by the end of 2024, offering new hope for effective weight control treatments.

For further insights into HK:2105 stock, check out TipRanks’ Stock Analysis page.